Comparative Pharmacology
Head-to-head clinical analysis: GENTACIDIN versus HUMATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTACIDIN versus HUMATIN.
GENTACIDIN vs HUMATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis.
Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
5-7 mg/kg IV every 24 hours.
15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.
None Documented
None Documented
2-3 hours in adults with normal renal function; extended to 24-48 hours in anuria or severe renal impairment, requiring dose adjustment.
2-3 hours (serum half-life of absorbed fraction); clinically negligible due to minimal systemic absorption
Renal: 95-98% unchanged via glomerular filtration; biliary/fecal: <2%.
Primarily unchanged in feces (~90%); small amount absorbed is excreted renally as unchanged drug (~1%)
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic